Nakamura S, Minami A, Fujimoto K, Kojima T
Research Laboratories, Dainippon Pharmaceutical Co., Ltd., Osaka, Japan.
Antimicrob Agents Chemother. 1989 Oct;33(10):1804-10. doi: 10.1128/AAC.33.10.1804.
Combination effects of recombinant human interleukin-1 alpha with ceftazidime, moxalactam, gentamicin, enoxacin, amphotericin B, miconazole, or an immunoglobulin preparation were evaluated in systemic infections with Pseudomonas aeruginosa, Klebsiella pneumoniae, and Candida albicans in normal mice and systemic infection with P. aeruginosa in mice with leukopenia induced by preadministration of cyclophosphamide. Synergistic effects were generally observed at interleukin-1 alpha doses as low as 1 to 30 ng per mouse with most combinations. The results show the possibility that recombinant human interleukin-1 alpha could be of help for treating obstinate infections not successfully treated with antimicrobial agents alone.
在正常小鼠的铜绿假单胞菌、肺炎克雷伯菌和白色念珠菌全身性感染以及预先给予环磷酰胺诱导白细胞减少的小鼠的铜绿假单胞菌全身性感染中,评估了重组人白细胞介素-1α与头孢他啶、莫拉酰胺、庆大霉素、依诺沙星、两性霉素B、咪康唑或免疫球蛋白制剂的联合效应。大多数组合在低至每只小鼠1至30纳克的白细胞介素-1α剂量下通常观察到协同效应。结果表明,重组人白细胞介素-1α有可能有助于治疗单独使用抗菌药物未能成功治疗的顽固性感染。